4SC to Present Results of Clinical Phase II Study with Resminostat in HL
Complete the form below to unlock access to ALL audio articles.
4SC AG has announced that the company will present results of the clinical Phase II SAPHIRE study with its anti-cancer compound resminostat in patients with Hodgkin's lymphoma (HL) at the 2011 Annual Meeting of the American Society of Hematology (ASH) in San Diego, California.
Results will be presented in a poster session to be held on 11 December 2011 at 6 pm (PST).
The open-label, single-arm, international study evaluated safety, pharmacokinetics, biomarkers, and efficacy of resminostat monotherapy treatment in, as of today, 34 evaluable patients with advanced HL.
Patients enrolled in the trial had either relapsed after high dose chemotherapy and/or autologous stem cell transplantation (ASCT) or had become refractory to treatment, and had on average received 6 prior treatments.
An overall response rate (ORR) of 35.3% was observed and more than half (55.9%) of the patients received a clinical benefit from resminostat treatment, suggesting a substantial anti-tumour activity.
Furthermore, resminostat showed a very good safety and tolerability profile. Currently one further patient is still under treatment and has achieved stabilization of disease for now 30 weeks.
From 11 December 2011, 6 pm (PST) (that is 12 December 2011, 3 am (CET) in Germany), the scientific poster with the detailed study results presented at the ASH meeting can be downloaded from http://www.4sc.de/product-pipeline/publications-posters/resminostat.
